Phase 2 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are able to understand and willing to sign a consent form agreeing to take part in the study
- You have been diagnosed with prostate cancer (confirmed by a tissue sample/biopsy)
- Your doctor has decided that your prostate cancer is advanced enough to be treated with one of the specific medications used in this trial (abiraterone acetate plus prednisone, or darolutamide)
- You are currently receiving hormone-blocking treatment for prostate cancer, or have had both testicles surgically removed
- You are reasonably active and able to care for yourself, with a moderate to good level of physical functioning (confirm with trial site)
- You are 18 years of age or older at the time of signing the consent form
- Your doctor estimates you are expected to live at least 6 more months
- You are able and willing to attend all required study visits and follow all study procedures for the full length of the trial
Who may not be able to join:
- You have already been taking abiraterone or darolutamide for more than 28 days before starting the enrollment process
- You have any condition that, in your doctor's opinion, would prevent you from fully understanding and giving consent, or that could put your safety at risk or make it hard to follow the trial requirements
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mamta Parikh, University of California, Davis
Phone: 916-382-6970
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of grade 3 or higher adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.